Payment overview · 2025
General Payments
1 reported records · 1 companies
Healthcare provider profile · identity verified
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · MARKS, MS · NPI 1407109945
Verified facts
CMS Open Payments records show Lea Ann Byrd, APRN received $15.25 in general payments during 2025 across 1 reported records.
ABBVIE INC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Payment overview · 2025
1 reported records · 1 companies
Separate record types
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.25 | 100.0% | 1 | 2025 |
What were the payments for?
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $15.25 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
95 | 26 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 481 | 271 |
| Amlodipine Besylate | Amlodipine Besylate | 462 | 130 |
| Potassium Chloride | Potassium Chloride | 431 | 141 |
| Montelukast Sodium | Montelukast Sodium | 376 | 134 |
| Gabapentin | Gabapentin | 365 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 362 | 110 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 350 | 113 |
| Losartan Potassium | Losartan Potassium | 343 | 92 |
| Atorvastatin Calcium | Atorvastatin Calcium | 317 | 90 |
| Levothyroxine Sodium | Levothyroxine Sodium | 314 | 83 |
| Furosemide | Furosemide | 304 | 101 |
| Hydrochlorothiazide | Hydrochlorothiazide | 287 | 71 |
| Fluconazole | Fluconazole | 277 | 167 |
| Metformin Hcl | Metformin Hcl | 221 | 53 |
| Carvedilol | Carvedilol | 215 | 60 |
| Levofloxacin | Levofloxacin | 197 | 141 |
| Lisinopril | Lisinopril | 178 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 178 | 55 |
| Pioglitazone Hcl | Pioglitazone Hcl | 168 | 40 |
| Clonidine Hcl | Clonidine Hcl | 167 | 45 |
| Omeprazole | Omeprazole | 161 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 160 | 46 |
| Azithromycin | Azithromycin | 155 | 132 |
| Diclofenac Sodium | Diclofenac Sodium | 152 | 71 |
| Fluticasone Propionate | Fluticasone Propionate | 145 | 74 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 140 | 64 |
| Glimepiride | Glimepiride | 132 | 33 |
| Amoxicillin | Amoxicillin | 128 | 101 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 118 | 91 |
| Metoprolol Tartrate | Metoprolol Tartrate | 106 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 105 | 63 |
| Enalapril Maleate | Enalapril Maleate | 102 | 21 |
| Linzess | Linaclotide | 95 | 26 |
| Allopurinol | Allopurinol | 94 | 21 |
| Azelastine Hcl | Azelastine Hcl | 93 | 77 |
| Simvastatin | Simvastatin | 93 | 23 |
| Alendronate Sodium | Alendronate Sodium | 92 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 89 | 23 |
| Jardiance | Empagliflozin | 88 | 26 |
| Methocarbamol | Methocarbamol | 88 | 65 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 87 | 69 |
| Farxiga | Dapagliflozin Propanediol | 87 | 21 |
| Meloxicam | Meloxicam | 87 | 31 |
| Ozempic | Semaglutide | 87 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 85 | 22 |
| Mupirocin | Mupirocin | 85 | 56 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 84 | 70 |
| Clopidogrel | Clopidogrel Bisulfate | 84 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 83 | 26 |
| Methylprednisolone | Methylprednisolone | 80 | 66 |
| Glipizide | Glipizide | 79 | 14 |
| Spironolactone | Spironolactone | 79 | 26 |
| Cephalexin | Cephalexin | 75 | 52 |
| Eliquis | Apixaban | 74 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | 16 |
| Trulicity | Dulaglutide | 72 | 13 |
| Ibuprofen | Ibuprofen | 71 | 55 |
| Famotidine | Famotidine | 67 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 63 | 34 |
| Tramadol Hcl | Tramadol Hcl | 63 | 38 |
| Colchicine | Colchicine | 62 | 14 |
| Trazodone Hcl | Trazodone Hcl | 60 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 59 | 21 |
| Januvia | Sitagliptin Phosphate | 59 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 57 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 56 | 18 |
| Benazepril Hcl | Benazepril Hcl | 55 | 14 |
| Cefdinir | Cefdinir | 55 | 50 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 55 | 47 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 55 | 53 |
| Ezetimibe | Ezetimibe | 54 | 18 |
| Glyburide | Glyburide | 52 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 52 | 16 |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 50 | 46 |
| Xarelto | Rivaroxaban | 50 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 49 | 25 |
| Atenolol | Atenolol | 48 | 12 |
| Donepezil Hcl | Donepezil Hcl | 48 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 11 |
| Lansoprazole | Lansoprazole | 46 | 20 |
| Lovastatin | Lovastatin | 46 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 46 | 26 |
| Tradjenta | Linagliptin | 46 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 45 | 42 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | 16 |
| Sucralfate | Sucralfate | 45 | 28 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 44 | 17 |
| Glipizide Er | Glipizide | 43 | 12 |
| Methimazole | Methimazole | 43 | 11 |
| Methenamine Hippurate | Methenamine Hippurate | 42 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 41 | 16 |
| Alprazolam | Alprazolam | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 25 |
| Megestrol Acetate | Megestrol Acetate | 39 | 13 |
| Sertraline Hcl | Sertraline Hcl | 39 | 12 |
| Celecoxib | Celecoxib | 38 | 12 |
| Clonazepam | Clonazepam | 38 | suppressed |
| Lorazepam | Lorazepam | 38 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | 26 |
| Pregabalin | Pregabalin | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | 13 |
| Gemfibrozil | Gemfibrozil | 35 | suppressed |
| Ondansetron Odt | Ondansetron | 34 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | suppressed |
| Metronidazole | Metronidazole | 32 | 29 |
| Verapamil Er | Verapamil Hcl | 32 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 31 | 15 |
| Mirtazapine | Mirtazapine | 30 | suppressed |
| Nystatin | Nystatin | 28 | 16 |
| Clarithromycin | Clarithromycin | 27 | 27 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 21 |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Indomethacin | Indomethacin | 26 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Levetiracetam | Levetiracetam | 24 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 22 | 17 |
| Terbinafine Hcl | Terbinafine Hcl | 22 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 20 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 20 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 19 | 17 |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 18 | 12 |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Ofloxacin | Ofloxacin | 15 | 15 |
| Permethrin | Permethrin | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Acarbose | Acarbose | 14 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Larin Fe | Norethindrone-E.Estradiol-Iron | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
Timeline
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $15.25 · 1 records | ABBVIE INC. | VRAYLAR | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error